All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Subsequent Therapy Shows No Difference in OS Following IO/TKI-Based Treatment in RCC

August 19th 2024

Neil J. Shah, MBBS, discusses real-world outcomes of patients with metastatic RCC receiving treatment in the post-IO/TKI setting following progression.

Adagrasib/Cetuximab Combo Marks the Beginning of the RAS-Targeting Era in CRC

August 19th 2024

Rona Yaeger, MD, details the FDA approval of adagrasib plus cetuximab in KRAS G12C-mutated colorectal cancer and how the approval will advance the field.

Case Studies: Three follicular lymphoma cases treated with oral tazemetostat

August 19th 2024

Retrospective Study Exemplifies the Environmental and Health Impacts of Decentralizing Cancer Care

August 18th 2024

Andrew Hantel, MD, discusses environmental and health impacts of decentralizing cancer care in response to high emissions generated by US health care.

Copper Depletion Combats Metastatic Recurrence in High-Risk TNBC

August 17th 2024

Linda T. Vahdat, MD, discusses research with copper depletion in patients with high-risk triple-negative breast cancer.

Potentially Modifiable Eligibility Criteria Drive Enrollment Disparities in AML Clinical Trials

August 16th 2024

Andrew Hantel, MD, discusses the evaluation of eligibility criteria in acute myeloid leukemia clinical trials that may perpetuate racial disparities.

USC Norris Comprehensive Cancer Center to Open Radiation Oncology and Imaging Center in Newport Beach

August 16th 2024

The new USC Norris location will feature new-to-market technology not yet available in Orange County

FDA Grants Priority Review to Vimseltinib in Tenosynovial Giant Cell Tumor

August 16th 2024

The FDA has accepted an NDA for vimseltinib for the treatment of patients with tenosynovial giant cell tumor, with a PDUFA date of February 17, 2025.

Tafasitamab Plus R2 Improves PFS in Relapsed/Refractory Follicular Lymphoma

August 16th 2024

Tafasitamab plus lenalidomide and rituximab improved progression-free survival vs lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma.

Retrospective Study Reveals Enzalutamide Yields More Favorable Outcomes vs Abiraterone in mCRPC

August 16th 2024

Enzalutamide led to improved OS, PCS, TTS, and TTR vs abiraterone acetate in patients with metastatic castration-resistant prostate cancer.

Time to Next Therapy Demonstrates Potential as an Intermediate End Point in Metastatic RCC

August 16th 2024

Renee Maria Saliby, MD, MS, discusses potential intermediate end points for overall survival in previously treated metastatic renal cell carcinoma.

Optimize Interventions to Get a Step Ahead of Financial Toxicity in Cancer Care

August 16th 2024

Investigators are developing preventive interventions to identify patients most at risk for financial toxicity and offer them assistance.

Acalabrutinib With/Without Obinutuzumab Is Effective in Higher-Risk Chronic Lymphocytic Leukemia

August 16th 2024

Acalabrutinib-containing regimens demonstrated long-term efficacy with a tolerable safety profile in higher-risk chronic lymphocytic leukemia.

FDA Approves Perioperative Durvalumab Plus Chemotherapy in Resectable NSCLC

August 15th 2024

The FDA has approved neoadjuvant durvalumab plus chemotherapy, followed by adjuvant durvalumab, for select resectable non–small cell lung cancer.

An Embarrassment of Riches in Oncology With Wayward Decision Support: A Recipe for Disaster?

August 15th 2024

Head over to our YouTube channel to watch Dr Markman discuss the effects of information overload in oncology: https://rb.gy/bvumdn.

Linvoseltamab Demonstrates Deep, Durable Responses in R/R Myeloma Ahead of FDA Action Date

August 15th 2024

Suzanne Lentzsch, MD, PhD, discusses updated data from the LINKER-MM1 study of linvoseltamab in relapsed/refractory multiple myeloma.

Ongoing Research Aims to Unveil the Optimal Use of Neoadjuvant and Adjuvant Therapies in TNBC

August 15th 2024

Linda T. Vahdat, MD, discusses investigations of ADCs and targeted agents in patients with TNBC and residual disease following chemoimmunotherapy.

Fox Chase Cancer Center and Lewis Katz School of Medicine Researchers Identify Where to Target Interventions to Reduce Disparities in Aggressive Prostate Cancer

August 15th 2024

Researchers at Fox Chase Cancer Center have identified factors that could decrease incidence of prostate cancer in areas where rates are highest.

Ivonescimab Under Priority Review by China’s NMPA for Frontline PD-L1–Positive NSCLC

August 15th 2024

Ivonescimab has been granted priority review in China for the frontline treatment of patients with PD-L1–positive locally advanced or metastatic NSCLC.

FDA Grants Priority Review to Durvalumab for LS-SCLC After Concurrent Chemoradiotherapy

August 15th 2024

The FDA granted priority review to durvalumab in limited-stage small cell lung cancer after platinum-based concurrent chemoradiotherapy.